FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
This article was originally published in The Pink Sheet Daily
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
You may also be interested in...
Do Ads Noting A Drug’s ‘Targeted’ Mechanism Of Action Impact Perceptions Of the Product?
US FDA will study how presentations of a fictitious cancer drug’s targeted mechanism of action affect consumer and provider interest in the drug and their understanding of its benefits and risks. Another study will assess how consumers and primary care physicians interpret Rx drug names.
DTC Safety Messages Could Vary By Platform As FDA Considers Screen Size
Both tablets and huge TVs have proliferated since the last research of the impact of superimposed text.
FDA's Rx Promotion Citation Drought Continued In 2015
First Amendment litigation and guidance document work may be factors behind decline.